Gynecologic Cancer InterGroup (GCIG) Consensus Review: Uterine and Ovarian Leiomyosarcomas

Objectives The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management. Methods Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made. Results The approach to management of uterine and ovarian leiomyosarcoma management is reviewed. Conclusions Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.

[1]  E. Keung,et al.  External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma , 2013, Cancer.

[2]  J. Wathen,et al.  Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma , 2013, Cancer.

[3]  R. Rouzier,et al.  How to differentiate benign from malignant myometrial tumours using MR imaging , 2013, European Radiology.

[4]  C. Haie-meder,et al.  A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  I. Shih,et al.  Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. , 2013, Gynecologic oncology.

[6]  R. Goldbohm,et al.  The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium , 2013, British Journal of Cancer.

[7]  E. Oliva,et al.  Recent developments in uterine mesenchymal neoplasms , 2013, Histopathology.

[8]  J. Blay,et al.  Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). , 2012, The oncologist.

[9]  E. Keung,et al.  External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS). , 2012 .

[10]  R. Barakat,et al.  Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. , 2012, Gynecologic oncology.

[11]  E. Weiderpass,et al.  Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases. , 2012, Maturitas.

[12]  R. Barakat,et al.  Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. , 2012, Gynecologic oncology.

[13]  Rakesh Kumar,et al.  Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging , 2012, Nuclear medicine communications.

[14]  Alexia Iasonos,et al.  A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma , 2012, Cancer.

[15]  D. Sugarbaker,et al.  Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. , 2011, The Annals of thoracic surgery.

[16]  Sun-Kyung Park,et al.  The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. , 2011, Gynecologic oncology.

[17]  A. Padhy,et al.  Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas , 2011, Acta radiologica.

[18]  P. Branton,et al.  Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus: A Detailed Analysis of 27 Cases , 2011, American Journal of Surgical Pathology.

[19]  G. Israel,et al.  MRI appearance of mesenchymal tumors of the uterus. , 2010, European journal of radiology.

[20]  J. Prat,et al.  Uterine sarcomas: a review. , 2010, Gynecologic Oncology.

[21]  L. Jacks,et al.  Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Collin,et al.  Prognostic Factors in Early-Stage Leiomyosarcoma of the Uterus , 2009, International Journal of Gynecologic Cancer.

[24]  P. Rose,et al.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. , 2008, Gynecologic oncology.

[25]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[26]  R. Mannel,et al.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. , 2008, Gynecologic oncology.

[27]  D. Metzinger,et al.  Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. , 2007, The Journal of reproductive medicine.

[28]  R. Barakat,et al.  Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease , 2007, International Journal of Gynecologic Cancer.

[29]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Rennert,et al.  The risk of developing uterine sarcoma after tamoxifen use , 2007, International Journal of Gynecologic Cancer.

[31]  Eero Pukkala,et al.  Analysis of fumarate hydratase mutations in a population‐based series of early onset uterine leiomyosarcoma patients , 2006, International journal of cancer.

[32]  P. Pairolero,et al.  Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. , 2006, The Annals of thoracic surgery.

[33]  M. Tucker,et al.  Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Goldblum,et al.  Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas: An Immunohistochemical Study , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[35]  A. Olshen,et al.  Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma , 2004, Cancer.

[36]  R. Kudo,et al.  Preoperative Diagnosis and Treatment Results in 106 Patients with Uterine Sarcoma in Hokkaido, Japan , 2004, Oncology.

[37]  T. Fujisawa,et al.  Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. , 2004, The Journal of thoracic and cardiovascular surgery.

[38]  E. Oliva,et al.  The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. , 2004, Gynecologic oncology.

[39]  J. Lucci,et al.  Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. , 2004, Gynecologic oncology.

[40]  R. Barakat,et al.  Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. , 2003, Gynecologic oncology.

[41]  E. Venkatraman,et al.  Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. , 2002, Gynecologic oncology.

[42]  C. Haie-meder,et al.  Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma , 2000, Cancer.

[43]  G. Sutton,et al.  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[44]  R. Kempson,et al.  Problematic Uterine Smooth Muscle Neoplasms: A Clinicopathologic Study of 213 Cases , 1994, The American journal of surgical pathology.

[45]  B. Goff,et al.  Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. , 1993, Gynecologic oncology.

[46]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study , 1992 .

[47]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. , 1992, American journal of obstetrics and gynecology.

[48]  P. Disaia,et al.  Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin Versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group) , 1985, Cancer.